131 related articles for article (PubMed ID: 20627009)
1. [Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer].
Xu L; Liu YH; Ye JM; Zhao JX; Duan XN; Zhang LB; Zhang H; Wang YH
Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(6):450-3. PubMed ID: 20627009
[TBL] [Abstract][Full Text] [Related]
2. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
3. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
[TBL] [Abstract][Full Text] [Related]
4. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Sonnenblick A; Francis PA; Azim HA; de Azambuja E; Nordenskjöld B; Gutiérez J; Quinaux E; Mastropasqua MG; Ameye L; Anderson M; Lluch A; Gnant M; Goldhirsch A; Di Leo A; Barnadas A; Cortes-Funes H; Piccart M; Crown J
Eur J Cancer; 2015 Aug; 51(12):1481-9. PubMed ID: 26074397
[TBL] [Abstract][Full Text] [Related]
5. Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm.
Bellati F; Napoletano C; Gasparri ML; Panici PB; Nuti M
J Clin Oncol; 2010 Sep; 28(27):e471-2; author reply e473. PubMed ID: 20585098
[No Abstract] [Full Text] [Related]
6. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
[TBL] [Abstract][Full Text] [Related]
7. [Factors related with pathological complete response of neoadjuvant chemotherapy in primary breast cancer].
Cheng YJ; Ye JM; Xu L; Zhao JX; Duan XN; Liu YH
Zhonghua Wai Ke Za Zhi; 2013 Apr; 51(4):339-43. PubMed ID: 23895756
[TBL] [Abstract][Full Text] [Related]
8. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
9. [Medical treatment of early breast cancer: chemotherapy].
Ejlertsen B; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
Wurster M; Ruoff A; Meisner C; Seeger H; Vogel U; Juhasz-Böss I; Solomayer E; Wallwiener D; Fehm T; Neubauer H
Oncol Rep; 2010 Sep; 24(3):653-9. PubMed ID: 20664970
[TBL] [Abstract][Full Text] [Related]
12. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
[TBL] [Abstract][Full Text] [Related]
13. [Gastrointestinal injuries in patients with breast cancer treated with chemotherapy].
Koroleva IA; Vel'sher LZ; Kaziulin AN; Kucheriavyĭ IuA; Oganesian TS
Vopr Onkol; 2010; 56(2):206-9. PubMed ID: 20552899
[No Abstract] [Full Text] [Related]
14. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.
Shao N; Wang S; Yao C; Xu X; Zhang Y; Zhang Y; Lin Y
Breast; 2012 Jun; 21(3):389-93. PubMed ID: 22542064
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
16. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
Toi M; Saeki T; Aogi K; Sano M; Hatake K; Asaga T; Tokuda Y; Mitsuyama S; Kimura M; Kobayashi T; Tamura M; Tabei T; Shin E; Nishimura R; Ohno S; Takashima S
Jpn J Clin Oncol; 2005 Jun; 35(6):310-5. PubMed ID: 15930037
[TBL] [Abstract][Full Text] [Related]
17. Taxanes and anthracyclines in early breast cancer: which first?
Wildiers H; Forceville K; Paridaens R; Joensuu H
Lancet Oncol; 2010 Mar; 11(3):219-20. PubMed ID: 20202604
[No Abstract] [Full Text] [Related]
18. Distribution of podoplanin-positive tumor vessels predicts disease-specific survival of node-positive breast cancer patients treated with anthracyclines and/or taxanes.
Niemiec JA; Adamczyk A; Ambicka A; Mucha-Małecka A; Wysocki WM; Ryś J
Cancer Invest; 2014 Jun; 32(5):168-77. PubMed ID: 24605901
[TBL] [Abstract][Full Text] [Related]
19. [Predictive factors of response to anthracyclines neoadjuvant chemotherapy in breast cancer].
Bensouda Y; Ismaili N; Ahbeddou N; El Hassani K; Chenna M; Sbitti Y; Boutayeb S; Errihani H
Gynecol Obstet Fertil; 2011 Feb; 39(2):81-6. PubMed ID: 21324724
[TBL] [Abstract][Full Text] [Related]
20. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
